275778
Imidazo[1,2-a]pyridine
99%
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C7H6N2
CAS Number:
Molecular Weight:
118.14
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
99%
Form:
liquid
Quality Level
assay
99%
form
liquid
refractive index
n20/D 1.626 (lit.)
bp
103 °C/1 mmHg (lit.)
density
1.165 g/mL at 25 °C (lit.)
SMILES string
c1ccn2ccnc2c1
InChI
1S/C7H6N2/c1-2-5-9-6-4-8-7(9)3-1/h1-6H
InChI key
UTCSSFWDNNEEBH-UHFFFAOYSA-N
General description
In vivo anti-trypanosomal activity of imidazo[1,2-a]pyridiness in the STIB900 mouse model has been investigated.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
235.4 °F - closed cup
flash_point_c
113 °C - closed cup
ppe
Eyeshields, Gloves, type ABEK (EN14387) respirator filter
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Katherine A Abrahams et al.
PloS one, 7(12), e52951-e52951 (2013-01-10)
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB. Through the use of
Martina Hieke et al.
Bioorganic & medicinal chemistry letters, 22(5), 1969-1975 (2012-02-14)
A novel class of 5-lipoxygenase (5-LO) inhibitors characterized by a central imidazo[1,2-a]pyridine scaffold, a cyclohexyl moiety and an aromatic system, is presented. This scaffold was identified in a virtual screening study and exhibits promising inhibitory potential on the 5-LO. Here
Kyle A Emmitte et al.
Bioorganic & medicinal chemistry letters, 19(3), 1004-1008 (2008-12-23)
The optimization of imidazo[1,2-a]pyridine inhibitors as potent and selective inhibitors of IGF-1R is presented. Further optimization of oral exposure in mice is also discussed. Detailed selectivity, in vitro activity, and in vivo PK profiles of an optimized compound is also